Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.
Chinese biotech BeiGene is hoping to trade on the Nasdaq, filing for an IPO worth more than $150 million to support its pipeline of targeted cancer drugs.
Eye Tech Care has nabbed a commitment from China-focused investor Everpine Capital to invest about €24.8 million ($26.9 million) in two rounds. The firm has already invested an initial, undisclosed amount and it's working with the Lyon-based startup to gain a regulatory approval from the China Food and Drug Administration for its noninvasive glaucoma ultrasound treatment, which is already marketed in Europe.
Shanghai-headquartered drug developer Zai Lab said it locked up more than $100 million in Series B financing, raising cash from a syndicate including OrbiMed and Sequoia Capital.
Chinese drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $1 billion, according to reports, joining a slew of local biopharma companies headed to the public markets.
In December 2015, the China FDA approved the first vaccine against the virus that causes hand, foot and mouth disease, a common infectious disease often found in children. But competition was not far behind: the agency approved a second vaccine against the virus on Monday, this one developed by Sinovac.
Jiangsu Hansoh Pharmaceutical, a Chinese drug developer, is moving toward a Hong Kong IPO worth up to $3 billion, according to Dow Jones.
After Q2's glacial emerging markets growth, industry watchers wondered just how slow pharma could go in developing countries. As it turns out, they found a way to decelerate in Q3.
Jin'ge (Chinese for "golden spear") from China's Guangzhou Baiyunshan is said to be on track to eclipse sales of Pfizer's Viagra in China in a few years with a price that is 60% less than the branded erectile dysfunction drug.
GlaxoSmithKline, post-corruption scandal, has been working hard to clean up its act in China, overhauling its sales practices to wipe out bribery--and its general manager in the country, Hervé Gisserot, has said he expects to see other companies follow suit. But with sales hanging in the balance, some might not be sure just how to do that.